menu
    • menu

    Company profile for SparingVision

    NEW Drugs in Dev: 2
    Granules India Limited has high volume world-class facilities for APIs, PFIs, & FDFs, serving customers in over 80 countries.

    Virtual Booth

    Contact Supplier

    Lupin Manufacturing Solutions – delivering high-quality APIs & end-to-end CDMO services for faster, cost-effective drug development.

    Virtual Booth

    Contact Supplier

    Mission CDMO team brings reliability, resourcefulness, & responsiveness in executing your development project.

    Virtual Booth

    Contact Supplier

    Egis is a Hungarian generic pharma company with 110 years history. Our activities incorporate all areas of the pharma value chain.

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-2026-02-09

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    SparingVision is a biotechnology company focused on the discovery and development of innovative therapies for the treatment of blinding inherited retinal diseases. SparingVision is developing SPVN06, a gene-independent drug candidate to treat retinitis pigmentosa, the most common inherited retinal degeneration. There is currently no treatment to treat all genetic forms of this rare retinal disease that leads to blindness and a...
    SparingVision is a biotechnology company focused on the discovery and development of innovative therapies for the treatment of blinding inherited retinal diseases. SparingVision is developing SPVN06, a gene-independent drug candidate to treat retinitis pigmentosa, the most common inherited retinal degeneration. There is currently no treatment to treat all genetic forms of this rare retinal disease that leads to blindness and affects 40,000 people in France and nearly 2 million worldwide.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    SparingVisionFrance Flag
    Country
    Country
    France
    Address
    Address
    55, Rue de Lyon Paris, Ile-de-France 75012
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://sparingvision.com/
    Linkedin
    Linkedin
    https://fr.linkedin.com/company/sparingvision
    youtube
    YouTube
    Twitter
    Twitter
    https://x.com/SparingVision

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Clinical Outsourcing

    Clinical Outsourcing

    Not Confirmed

    envelop Contact Supplier

    Clinical Outsourcing

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Sparingvision Completes PRODYGY Trial Patient Dosing With SPVN06,
    Sparingvision Completes PRODYGY Trial Patient Dosing With SPVN06,

    09 Feb 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/02/09/3234407/0/en/SparingVision-Successfully-Completes-PRODYGY-Trial-Patient-Dosing-with-SPVN06-its-Novel-Neuroprotective-Gene-Therapy.html

    GLOBENEWSWIRE
    09 Feb 2026
    Share Share
    Sparingvision Initiates First SPVN20 Dosing in Nyrvana Trial
    Sparingvision Initiates First SPVN20 Dosing in Nyrvana Trial

    28 Oct 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/10/28/3175310/0/en/SparingVision-Doses-First-Patient-with-SPVN20-for-Advanced-Retinitis-Pigmentosa-in-NYRVANA-Trial.html

    GLOBENEWSWIRE
    28 Oct 2025
    Share Share
    SparingVision Reaches Final Dose Escalation Step in PRODYGY Trial
    SparingVision Reaches Final Dose Escalation Step in PRODYGY Trial

    24 Jan 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com//news-release/2024/01/24/2815094/0/en/SparingVision-Reaches-Final-Dose-Escalation-Step-in-PRODYGY-Trial-with-SPVN06-for-retinitis-pigmentosa.html

    GLOBENEWSWIRE
    24 Jan 2024
    Share Share
    SparingVision Reports +ve Initial Safety Data from the first cohort Ph I/II
    SparingVision Reports +ve Initial Safety Data from the first cohort Ph I/II

    30 Aug 2023

    // GLOBENEWSWIRE

    https://www.globenewswire.com//news-release/2023/08/30/2734166/0/en/SparingVision-Reports-Positive-Initial-Safety-Data-from-the-first-cohort-treated-in-its-PRODYGY-Phase-I-II-Gene-Therapy-Trial.html

    GLOBENEWSWIRE
    30 Aug 2023
    Share Share
    SparingVision sells ex vivo GIRK technology to Tenpoint Therapeutics
    SparingVision sells ex vivo GIRK technology to Tenpoint Therapeutics

    12 Jul 2023

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2023/07/12/2703375/0/en/SparingVision-sells-ex-vivo-GIRK-technology-to-Tenpoint-Therapeutics.html

    GLOBENEWSWIRE
    12 Jul 2023
    Share Share
    SparingVision appoints Joseph C. Papa as Chairman
    SparingVision appoints Joseph C. Papa as Chairman

    05 Apr 2023

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2023/04/05/2641518/0/en/SparingVision-appoints-Joseph-C-Papa-as-Chairman.html

    GLOBENEWSWIRE
    05 Apr 2023
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search